Sprint Bioscience (SPRINT.ST) Stock Analysis & AI Equity Report

Biotechnology SEK Explore free reports

Sprint Bioscience (SPRINT.ST) overview

Sprint Bioscience (SPRINT.ST) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of SEK 167m and operating profit of SEK 97.3m; the year-end share price was 1.47 SEK and market capitalisation was SEK 155m. Sprint Bioscience is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Sprint Bioscience's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 119mFY 2025
Share price1.47 SEKFY 2025 year end
RevenueSEK 167mFY 2025
Operating profitSEK 97.3mFY 2025
Net earningsSEK 91.7mFY 2025
Market capitalisationSEK 155mFY 2025 year end

About Sprint Bioscience

Sprint Bioscience is a Swedish drug-discovery company developing preclinical small-molecule programs, primarily for solid tumors, using fragment-based drug discovery. Its portfolio targets tumor metabolism, the tumor microenvironment and immuno-oncology, with programs including VRK1, VPS34, NNMT, DCPS and STK25; NNMT also addresses chronic kidney disease. It licenses programs to pharmaceutical partners and has an AI-platform agreement with Lilly TuneLab.

Generate the Sprint Bioscience report

Sprint Bioscience is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Sprint Bioscience and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Sprint Bioscience

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.